Assenagon Asset Management S.A. Has $84.77 Million Position in Boston Scientific Co. (NYSE:BSX)

Assenagon Asset Management S.A. reduced its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 75.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 949,033 shares of the medical equipment provider's stock after selling 2,948,084 shares during the period. Assenagon Asset Management S.A. owned about 0.06% of Boston Scientific worth $84,768,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Marshall Wace LLP grew its stake in shares of Boston Scientific by 115.9% in the 2nd quarter. Marshall Wace LLP now owns 6,720,480 shares of the medical equipment provider's stock worth $517,544,000 after acquiring an additional 3,608,158 shares in the last quarter. AustralianSuper Pty Ltd increased its position in shares of Boston Scientific by 4,292.3% during the third quarter. AustralianSuper Pty Ltd now owns 2,676,847 shares of the medical equipment provider's stock valued at $224,320,000 after buying an additional 2,615,903 shares during the period. Ameriprise Financial Inc. increased its position in shares of Boston Scientific by 30.0% in the second quarter. Ameriprise Financial Inc. now owns 7,899,610 shares of the medical equipment provider's stock worth $608,349,000 after purchasing an additional 1,824,405 shares during the last quarter. State Street Corp increased its position in shares of Boston Scientific by 2.3% in the third quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock worth $5,266,522,000 after purchasing an additional 1,389,172 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Boston Scientific by 98.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,205,368 shares of the medical equipment provider's stock worth $184,810,000 after purchasing an additional 1,091,561 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Up 1.3 %

NYSE:BSX traded up $1.26 during mid-day trading on Thursday, hitting $98.15. The company had a trading volume of 5,020,057 shares, compared to its average volume of 5,327,683. Boston Scientific Co. has a 1 year low of $59.85 and a 1 year high of $98.31. The firm has a market capitalization of $144.65 billion, a price-to-earnings ratio of 81.11, a PEG ratio of 2.48 and a beta of 0.80. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The business has a fifty day simple moving average of $90.57 and a 200-day simple moving average of $84.23.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same period last year, the firm earned $0.50 earnings per share. The company's revenue for the quarter was up 19.3% compared to the same quarter last year. Equities analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig sold 4,877 shares of the company's stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the transaction, the director now directly owns 39,398 shares in the company, valued at $3,610,038.74. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,989 shares of company stock worth $2,702,261. Company insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BSX shares. Morgan Stanley increased their price objective on Boston Scientific from $92.00 to $100.00 and gave the company an "overweight" rating in a research note on Thursday, October 24th. Stifel Nicolaus lifted their price target on Boston Scientific from $85.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, October 18th. Wells Fargo & Company boosted their target price on Boston Scientific from $98.00 to $100.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Finally, StockNews.com lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Monday, November 4th. Three analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Boston Scientific has an average rating of "Moderate Buy" and an average target price of $97.26.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.